Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Investigators will recruit patients suspected of community-acquired pneumonia at Haukeland University Hospital, Bergen, into a pragmatic randomized controlled trial to assess if provision of ultra-rapid, high-quality accurate molecular diagnostics with direct feedback to the clinician can facilitate pathogen-directed usage of antibiotics, shorten antibiotic exposure and admission time and is safe. Additionally, transcriptional and immune marker profiling of patients will guide appropriate management through a targeted focus on the individual patient's physical capacity, nutritional status and co- morbidities. The pragmatic design of this trial together with broad inclusion criteria and a straightforward intervention would make our results generalisable to other similar centres.
Description: Binary outcome: yes: it was provided/no: it was not provided
Measure: The provision of pathogen-directed treatment based on a microbiological test result deemed as clinically relevant within 48 hours of receipt of respiratory samples. Time: "Up to 72 hours"Description: Quantitative outcome (measured in hours): time from receipt of respiratory specimens to provision of pathogen-directed treatment based on a microbiological test result deemed as clinically relevant or an elapse of 48 hours, whichever event came first.
Measure: Time in hours from receipt of respiratory specimens to receiving pathogen-directed treatment Time: "Up to 72 hours"Description: Duration of antibiotic use in days
Measure: Duration of antibiotic use in days Time: "Up to 4 weeks"Description: Proportion of patients receiving narrow-spectrum antibiotics within 48 hours from study inclusion
Measure: Proportion of patients receiving narrow-spectrum antibiotics within 48 hours from study inclusion Time: "Up to 4 weeks"Description: Proportion of patients receiving a single dose of antibiotics
Measure: Proportion of patients receiving a single dose of antibiotics Time: "Up to 1 week"Description: Proportion of patients receiving ≤48 h of antibiotics
Measure: Proportion of patients receiving ≤48 h of antibiotics Time: "Up to 1 week"Description: Proportion of patients receiving intravenous antibiotics
Measure: Proportion of patients receiving intravenous antibiotics Time: "Up to 1 week"Description: Duration of intravenous antibiotics in days
Measure: Duration of intravenous antibiotics in days Time: "Up to 4 weeks"Description: Proportion of cases where the UR-MT results were used to guide treatment
Measure: Proportion of cases where the UR-MT results were used to guide treatment Time: "Up to 1 week"Description: Time in days to isolation or de-isolation
Measure: Time in days to isolation or de-isolation Time: "Up to 2 weeks"Description: Duration of "door-to-needle time" in hours
Measure: Duration of "door-to-needle time" in hours Time: "Up to 1 week"Description: Length of hospital stay in days
Measure: Length of hospital stay in days Time: "Up to 3 months"Description: Proportion of 30-day readmission
Measure: Proportion of 30-day readmission Time: "Up to 30 days from discharge"Description: Proportion of 30- and 90-day and 1- and 5 year mortality
Measure: Proportion of 30- and 90-day and 1- and 5 year mortality Time: "Up to 1 month, 3 months, 1 and 5 years, from admission"Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports